Daklinza (daclatasvir) / BMS 
Welcome,         Profile    Billing    Logout  

7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daklinza (daclatasvir) / BMS
NCT04497649: Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Recruiting
2/3
100
RoW
Sofosbuvir, Mpiviropack, Sovaldy, soflanork, Daclatasvir, daklinza, daklanork
Tanta University
Covid19
04/21
04/21
NCT04460443: Sofosbuvir in Treatment of COVID 19

Recruiting
2/3
60
RoW
sofosbuvir, Mpiviropack, Sovaldy, soflanork, Sofosbuvir ledipsavir, mpiviropack plus, Daclatasvir, daklinza
Tanta University
COVID
08/21
08/21
REVOLUTIOn, NCT04468087: Antiviral Agents Against COVID-19 Infection

Completed
2/3
256
RoW
Atazanavir, Active Group, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg, Placebo Atazanavir, Placebo group, Placebo Daclatasvir 60 mg, Placebo Sofusbuvir + Daclatasvir 60 mg
Hospital do Coracao
COVID-19
08/21
08/21
2019-001431-31: A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection

Not yet recruiting
2
15
Europe
Daklinza, AT-527, na, Tablet, Daklinza
Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc.
HCV-Infected subjects, Hepatitis C, Diseases [C] - Virus Diseases [C02]
 
 
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Checkmark VHC 2015
Sep 2015 - Sep 2015: VHC 2015
Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark VHC 2014
More
No Longer Available
N/A
Europe
Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Checkmark
Jul 2014 - Jul 2014: 
No Longer Available
N/A
US
Daclatasvir (BMS-790052), Sofosbuvir
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT04122066: the Pulmonary Safety of Antihepatitis C Treatment

Not yet recruiting
N/A
50
NA
sofosbuvir \daclatsvir, Sovaldi\Daklinza
Assiut University
Hepatitis C
12/22
12/23

Download Options